Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma

Blood (2025) 146 (Supplement 1): 61.

https://doi.org/10.1182/blood-2025-61

Published: 2025

Journal Articles

Functional drug response profiling predicts clinical outcomes and shows utility for treatment stratification in AML

Blood (2025) 146 (Supplement 1): 1716.

https://doi.org/10.1182/blood-2025-1716

Published: 2025

Journal Articles

Brentuximab vedotin plus DHAP as effective salvage therapy in CD30+ peripheral T-cell lymphoma: A retrospective multicenter study

Thomas Weber, Sophy Denker, Julia Johanna Helmes, Susanne Ghandili, Kai Arne Plümer, Till Braun, Bastian von Tresckow, Ulrich Keller, Frederik Damm, Natali Pflug

Blood (2025) 146 (Supplement 1): 5425.

https://doi.org/10.1182/blood-2025-5425

Published: 2025

Journal Articles

Efficacy and safety of vipor (P) in relapsed or refractory large B-cell lymphoma

Thomas Oellerich, Rebecca Wurm-Kuczera, Shashwat Sahay, Meng Wang, Salaheddine Ali, Nazli Serin, Khouloud Kouidri, Donika Tahiri, Sebastian Scheich, Uta Brunnberg, David Winkler, Samixa Pudasaini, Zoi Saxonis, Atef Abdelhafez, Tatiana Borodina, Ulrike Krueger, David Böckle, Corinna Leng, Joseph Kauer, Isabelle Krämer, Konstantinos Christofyllakis, Marcel Teichert, Niklas Gebauer, Ulf Schnetzke, Thomas Weber, Lukas Frenzel, Anna-Carina Hund, Evgenii Shumilov, Thomas Melchardt, Florian Eisele, Mirjeta Berisha, Jakob Rudzki, Christian Scholz, Martin Schmidt-Hieber, Dimitrios Mougiakakos, Johannes Duell, Gerald Wulf, Christian Schmidt, Georg Lenz, Bastian von Tresckow, Hans Christian Reinhardt, Richard Greil, Lorenz Thurner, Peter Dreger, Martin Dreyling, Christiane Pott, Martina Rudelius, Oliver Weigert, Phillipp Strubel, Roland Eils, Antonia Busse, Ulrich Keller, Naveed Ishaque, Björn Chapuy

Blood (2025) 146 (Supplement 1): 3688.

https://doi.org/10.1182/blood-2025-3688

Published: 2025

Journal Articles

CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison

Blood (2025) 146 (Supplement 1): 4590.

https://doi.org/10.1182/blood-2025-4590

Published: 2025

Journal Articles

Characterization of two genetically distinct subtypes of C5 diffuse large B-cell lymphoma (DLBCL)

Meng Wang, Joji Shimono, Shashwat Sahay, Chidimma Agatha Akpa, Christina Schniederjohann, Julia Richter, Peter-Martin Bruch, Ulrich Dührsen, Michael Hummel, Andreas Rosenwald, Wolfram Klapper, Sascha Dietrich, Ulrich Keller, Björn Chapuy

Blood (2025) 146 (Supplement 1): 50.

https://doi.org/10.1182/blood-2025-50

Published: 2025

Journal Articles

A CD22-Specific T-Cell Receptor Enables Effective Adoptive T-Cell Therapy for B-cell malignancies

Simone Rhein, Neşe Çakmak-Görür, Corinna Grunert, Sarah Hayder Jalal Al-Tabatabaee, Nazli Serin, Matthias Leisegang, Stefanos Timiliotis, Luisa Sophie Ohlmeier, Cäcilia Freund, Gerald Willimsky, Frank Konietschke, Elisa Kieback, Sarah K Tasian, Bjoern Chapuy, Ulrich Keller, Thomas Blankenstein, Antonio Pezzutto, Antonia Busse

Blood blood.2025029329.

https://doi.org/10.1182/blood.2025029329

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis

Blood (2024) 144 (Supplement 1): 3818.

https://doi.org/10.1182/blood-2024-211227

Published: 2024

Journal Articles

Parallel Sequencing of Transposons and Transcriptomes in Single Cells for Genome-Wide Cancer Gene Discovery

Maximilian Holz, Bertram Klinger, Felix Stuckenbrok, Stefanos A. Bamopoulos, Sanket Gosavi, Caroline Bräuning, Janine Altmüller, Roland Rad, Torsten Haferlach, Nils Blüthgen, Ulrich Keller, Thomas Conrad, Francis Baumgartner

Blood (2024) 144 (Supplement 1): 1351.

https://doi.org/10.1182/blood-2024-206939

Published: 2024

Journal Articles

Data-Informed, Refined Immunophenotypic Classification of Adult T-Lineage Acute Lymphoblastic Leukemia

Stefan Habringer, Iva Todorova, Frederik Herzberg, Daniel Steiert, Arik Horne, Thomas Burmeister, Simon Haas, Ulrich Keller, Monika Brüggemann, Michaela Kotrova, Claudia D Baldus, Nicola Goekbuget, Martin Neumann, Stefan Schwartz

Blood (2024) 144 (Supplement 1): 1460.

https://doi.org/10.1182/blood-2024-202301

Published: 2024

Journal Articles

Tracing Clonal Hematopoiesis and Tumor-Specific Mutations in Hematopoietic Progenitors of B Cell Non-Hodgkin Lymphoma (NHL) Patients

Blood (2024) 144 (Supplement 1): 44.

https://doi.org/10.1182/blood-2024-199510

Published: 2024

Journal Articles

Targeted Treatment Additions Ibrutinib + Bortezomib + R-CHOP for Higher-Risk DLBCL: Efficacy, Feasibility and Molecular Signatures for Future Treatment Decisions

Blood (2024) 144 (Supplement 1): 6188.

https://doi.org/10.1182/blood-2024-207123

Published: 2024

Journal Articles

Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

Blood (2024) 144 (Supplement 1): 230.

https://doi.org/10.1182/blood-2024-209616

Published: 2024

Journal Articles

Real-World Evidence of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide with or without Polatuzumab (VIPOR(P)) for Relapsed/Refractory Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 6494.

https://doi.org/10.1182/blood-2024-200002

Published: 2024

Journal Articles

Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022

Francis Baumgartner, Constance Baer, Stefanos Bamopoulos, Edward Ayoub, Marietta Truger, Manja Meggendorfer, Miriam Lenk, Gregor Hoermann, Stephan Hutter, Heiko Müller, Wencke Walter, Martha-Lena Müller, Niroshan Nadarajah, Piers Blombery, Ulrich Keller, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach

Blood (2024) 143 (12): 1139–1156.

https://doi.org/10.1182/blood.2023021199

Published: 2024

Includes: Supplemental data

Journal Articles

Feasibility and Safety of the First-in-Human Chemotherapy-Light Combination of Rituximab, Polatuzumab Vedotin and Glofitamab in Previously Untreated Aggressive B-Cell Lymphoma Patients Above 60 Years of Age Ineligible for a Fully Dosed R-CHOP - R-Pola-Glo/Ikf-t062, a Study of the Austrian Group for Medical Tumor Therapy (AGMT-NHL-16) and the German Lymphoma Alliance (GLA2022-10)

Thomas Melchardt, Rebecca I Wurm-Kuczera, Bettina Altmann, Petra Pichler, Manuel Orlinger, Michael Panny, Luisa Wohn, Andreas Rosenwald, Dirk Hellwig, Sascha Dietrich, Bertram Glass, Georg Lenz, Ulrich Keller, Marita Ziepert, Richard Greil, Bjoern Chapuy

Blood (2023) 142 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2023-188854

Published: 2023

Journal Articles

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Blood (2022) 140 (Supplement 2): LBA-3.

https://doi.org/10.1182/blood-2022-171733

Published: 2022

Journal Articles

Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes - No Association of Clonal Hematopoiesis (CH) with Manufacturing Success

Blood (2022) 140 (Supplement 1): 7560–7562.

https://doi.org/10.1182/blood-2022-163360

Published: 2022

Journal Articles

Therapy-Related AML: Clinical/Biological Features and Long-Term Outcome in a Cohort of 1133 Adult AML Patients

Sophia Gross, Jana Ihlow, Leonie Busack, Kacper Adamiak, Jens F. Schrezenmeier, Julia Jesse, Michaela Schwarz, Anne Floercken, Kathrin Rieger, Jan Krönke, Philipp le Coutre, Vivien Boldt, Ann-Christin von Bruenneck, David Horst, Thomas Burmeister, Igor Wolfgang Blau, Ulrich Keller, Lars Bullinger, Joerg Westermann

Blood (2022) 140 (Supplement 1): 1291–1292.

https://doi.org/10.1182/blood-2022-164798

Published: 2022

Journal Articles

Combination Treatment of Venetoclax and Hypomethylating Agents (HMA) or Low-Dose Cytarabine (LDAC) for Patients with Acute Myeloid Leukemia (AML) - Real-World Data from Two German Academic Centers

Laura K. Schmalbrock, Krischan Braitsch, Paul Jung, Irmgard Bumeder, Philipp Kiewe, Jörg Westermann, Lars Bullinger, Ulrich Keller, Florian Bassermann, Jan Krönke, Kathrin Rieger, Katharina S. Goetze

Blood (2021) 138 (Supplement 1): 1257.

https://doi.org/10.1182/blood-2021-150943

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma

Functional drug response profiling predicts clinical outcomes and shows utility for treatment stratification in AML

Brentuximab vedotin plus DHAP as effective salvage therapy in CD30+ peripheral T-cell lymphoma: A retrospective multicenter study

Efficacy and safety of vipor (P) in relapsed or refractory large B-cell lymphoma

CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison

Characterization of two genetically distinct subtypes of C5 diffuse large B-cell lymphoma (DLBCL)

A CD22-Specific T-Cell Receptor Enables Effective Adoptive T-Cell Therapy for B-cell malignancies

Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis

Parallel Sequencing of Transposons and Transcriptomes in Single Cells for Genome-Wide Cancer Gene Discovery

Data-Informed, Refined Immunophenotypic Classification of Adult T-Lineage Acute Lymphoblastic Leukemia

Tracing Clonal Hematopoiesis and Tumor-Specific Mutations in Hematopoietic Progenitors of B Cell Non-Hodgkin Lymphoma (NHL) Patients

Targeted Treatment Additions Ibrutinib + Bortezomib + R-CHOP for Higher-Risk DLBCL: Efficacy, Feasibility and Molecular Signatures for Future Treatment Decisions

Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

Real-World Evidence of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide with or without Polatuzumab (VIPOR(P)) for Relapsed/Refractory Large B-Cell Lymphoma

Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes - No Association of Clonal Hematopoiesis (CH) with Manufacturing Success

Therapy-Related AML: Clinical/Biological Features and Long-Term Outcome in a Cohort of 1133 Adult AML Patients

Combination Treatment of Venetoclax and Hypomethylating Agents (HMA) or Low-Dose Cytarabine (LDAC) for Patients with Acute Myeloid Leukemia (AML) - Real-World Data from Two German Academic Centers

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only